ARS Pharmaceuticals’ (SPRY) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of ARS Pharmaceuticals (NASDAQ:SPRY) in a report released on Monday,RTT News reports.

Other equities analysts have also recently issued research reports about the company. Leerink Partners upped their price target on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Raymond James upped their price target on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. Finally, Oppenheimer started coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price target for the company. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $28.80.

ARS Pharmaceuticals Stock Performance

NASDAQ SPRY opened at $10.87 on Monday. ARS Pharmaceuticals has a twelve month low of $7.55 and a twelve month high of $18.51. The stock has a market capitalization of $1.06 billion, a PE ratio of -21.31 and a beta of 0.99. The stock has a 50-day simple moving average of $11.89 and a 200 day simple moving average of $13.19.

Insider Activity

In related news, COO Brian Dorsey sold 25,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $12.30, for a total transaction of $307,500.00. Following the sale, the chief operating officer now directly owns 6,024 shares in the company, valued at $74,095.20. This represents a 80.58 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sarina Tanimoto sold 100,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.16, for a total value of $1,316,000.00. Following the sale, the insider now owns 1,148,499 shares in the company, valued at approximately $15,114,246.84. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 402,272 shares of company stock worth $5,001,400. Company insiders own 40.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Bernard Wealth Management Corp. acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $27,000. KLP Kapitalforvaltning AS acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $73,000. BNP Paribas Financial Markets acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $75,000. Compass Capital Corp MA ADV acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $106,000. Finally, Ball & Co Wealth Management Inc. acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $105,000. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.